These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2748526)

  • 1. Efficiency of drug targeting: steady-state considerations using a three-compartment model.
    Boddy A; Aarons L; Petrak K
    Pharm Res; 1989 May; 6(5):367-72. PubMed ID: 2748526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of a linear recirculation model to drug targeting.
    Boddy AV; Aarons LJ
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):355-62. PubMed ID: 1875287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
    Gumbleton M; Oie S; Verotta D
    Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of drug action in disease states. XXI. Relationship between drug infusion rate and dose required to produce a pharmacologic effect.
    Klockowski PM; Levy G
    J Pharm Sci; 1987 Jul; 76(7):516-20. PubMed ID: 3668811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-dimensional mathematical model of non-linear dual-sorption of percutaneous drug absorption.
    George K
    Biomed Eng Online; 2005 Jul; 4():40. PubMed ID: 15992411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting the effect compartment through timing errors in drug administration.
    Nony P; Cucherat M; Boissel JP
    Trends Pharmacol Sci; 1998 Feb; 19(2):49-54. PubMed ID: 9550941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.
    Chen ML
    Clin Pharmacokinet; 2006; 45(10):957-64. PubMed ID: 16984210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state volume of distribution of two-compartment models with simultaneous linear and saturated elimination.
    Wu X; Nekka F; Li J
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):447-59. PubMed ID: 27405818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic considerations of regional administration and drug targeting: influence of site of input in target tissue and flux of binding protein.
    Rowland M; McLachlan A
    J Pharmacokinet Biopharm; 1996 Aug; 24(4):369-87. PubMed ID: 9044166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosage regimen design: pharmacodynamic considerations.
    Williams RL
    J Clin Pharmacol; 1992 Jul; 32(7):597-602. PubMed ID: 1639996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology and toxicology of novel drug delivery systems. Regulatory issues.
    Weissinger J
    Drug Saf; 1990; 5 Suppl 1():107-13. PubMed ID: 2182053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics in the design of controlled-release beads with acetaminophen as model drug.
    Hossain M; Ayres JW
    J Pharm Sci; 1992 May; 81(5):444-8. PubMed ID: 1403677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.
    Sheiner LB; Stanski DR; Vozeh S; Miller RD; Ham J
    Clin Pharmacol Ther; 1979 Mar; 25(3):358-71. PubMed ID: 761446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.
    Cirincione B; Edwards J; Mager DE
    AAPS J; 2017 Mar; 19(2):487-496. PubMed ID: 27896683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Derivation and presentation of formulas for drug concentrations in two-, three- and four-compartment pharmacokinetic models.
    Świętaszczyk C; Jødal L
    J Pharmacol Toxicol Methods; 2019; 100():106621. PubMed ID: 31351949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosage intervals based on mean residence times.
    Wagner JG
    J Pharm Sci; 1987 Jan; 76(1):35-8. PubMed ID: 3585720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic requirements for successful site-directed targeting of drugs.
    McMartin C
    Biotherapy; 1991; 3(1):9-23. PubMed ID: 2009218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane transport in hepatic clearance of drugs. I: Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes.
    Kwon Y; Morris ME
    Pharm Res; 1997 Jun; 14(6):774-9. PubMed ID: 9210196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.